JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Начало・Списък с акции・Novartis AG

Novartis AG

Затворен

145.15 -1.63

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

145

Максимум

145.48

Ключови измерители
By Trading Economics
Приходи	-1.5B 2.4B
Продажби	-1B 13B
P/E Средно за сектора	21.088 60.328
EPS	2.03
Дивидентна доходност	3.14
Марж на печалбата	18.064
Служители	75,267
EBITDA	-769M 5.1B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+16.77% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.14% 2.24%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.6B 291B
Предишно отваряне	146.78
Предишно затваряне	145.15

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 112.63 Подкрепа & съпротива

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 10:24 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27.03.2026 г., 06:36 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Biotech Excellergy for Up to $2 Billion

20.03.2026 г., 07:39 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion -- Update

20.03.2026 г., 06:30 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

16.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

24.04.2026 г., 05:20 ч. UTC

Печалби

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24.04.2026 г., 05:19 ч. UTC

Печалби

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24.04.2026 г., 05:19 ч. UTC

Печалби

Novartis: Prequalification Is a Process Run by the WHO

10.04.2026 г., 11:45 ч. UTC

Пазарно говорене

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Novartis Likely to Confirm Guidance -- Market Talk

30.03.2026 г., 09:37 ч. UTC

Пазарно говорене

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27.03.2026 г., 07:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27.03.2026 г., 06:22 ч. UTC

Придобивния, сливания и поглъщания

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27.03.2026 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27.03.2026 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27.03.2026 г., 06:03 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

27.03.2026 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Would Include Exl-111 Drug

27.03.2026 г., 06:01 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Strengthens Immunology Strategy in Food Allergy, Other IgE-driven Diseases

27.03.2026 г., 06:00 ч. UTC

Придобивния, сливания и поглъщания

Novartis Agrees to Buy Excellergy

23.03.2026 г., 15:27 ч. UTC

Пазарно говорене

Novartis's Share Strength Raises Bar for Drug Pipeline -- Market Talk

20.03.2026 г., 10:53 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Novartis Makes Meaningful Move With Breast-Cancer Deal -- Market Talk

20.03.2026 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Subject to Closing Conditions, Regulatory Approvals

20.03.2026 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Deal Should Close This Half

20.03.2026 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Acquisition Involves Takeover of Pikavation Therapeutics, Owner of SNV4818, Other Inhibitors

20.03.2026 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis Could Pay Further $1 Bln in Milestone Payments to Synnovation

20.03.2026 г., 06:03 ч. UTC

Придобивния, сливания и поглъщания

Novartis To Pay $2 Bln for Drug Upfront

20.03.2026 г., 06:03 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Acquisition Squares With Breast-Cancer Strategy

20.03.2026 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Novartis: SNV4818 Is Oral Drug Currently Being Evaluated in Phase 1/2 Study for Breast Cancer, Other Solid Tumors

20.03.2026 г., 06:01 ч. UTC

Придобивния, сливания и поглъщания

Novartis: SNV4818 pan-mutant--selective PI3K ALPHA Inhibitor for Treatment of Breast Cancer

20.03.2026 г., 06:01 ч. UTC

Придобивния, сливания и поглъщания

Novartis To Buy Inhibitor SNV4818 From Synnovation Therapeutics

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

16.77% нагоре

12-месечна прогноза

Среден 169.86 USD 16.77%

Висок 180 USD

Нисък 141 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Novartis AG през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 112.63Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.